Vir Biotechnology, Inc. (NASDAQ: VIR)

Vir Biotechnology, Inc. is a clinical stage biopharmaceutical company dedicated to harnessing the immune system to combat serious infectious diseases and cancer. The company discovers and develops therapeutic candidates that aim to enhance immune responses against viruses such as hepatitis delta and human immunodeficiency virus and to direct immune cells to destroy tumor cells in solid tumours. Its pipeline includes investigational antibody combinations for hepatitis delta and a series of masked T cell engagers targeting prostate, HER2 and EGFR expressing cancers. The firm relies on its internal antibody discovery engine and two core technology platforms to drive its research efforts.

Vir Biotechnology generates revenue primarily through collaboration and licensing agreements with pharmaceutical partners. These arrangements provide up front cash payments, equity investments and milestone payments tied to development, regulatory and sales achievements. The company also earns royalties on net sales of products that are commercialised by its partners. While it currently has no marketed products, future revenue will depend on the successful approval and sale of its pipeline candidates.

Vir Biotechnology occupies a niche in the biotechnology sector as a developer of immune modulating therapies that combine antibody engineering with proprietary masking technology. Its competitors in the hepatitis delta space include Gilead Sciences with its approved bulevirtide and other emerging firms pursuing alternative mechanisms. In oncology the company faces established players such as Roche, Johnson & Johnson and Novartis that are developing antibody drug conjugates and bispecific antibodies for similar tumour targets. Vir Biotechnology’s competitive edge stems from its dAIsY platform which uses artificial intelligence to optimise antibody properties and its exclusive licence to the PRO XTEN masking system that aims to improve the safety and potency of T cell engagers by limiting activity to the tumour microenvironment.

The company’s customers are primarily its collaboration partners which include Norgine for the hepatitis delta combination, Astellas for the prostate cancer T cell engager, GSK for Covid related antibodies and Alnylam for hepatitis B siRNA programs. These partners provide funding, share development costs and hold commercial rights in specific territories. In the future, should its products reach the market, the company will serve patients, healthcare providers and public health systems seeking treatments for serious viral infections and cancer.